Browsing: Lilly

Pharmaceutical giant Eli Lilly and biomanufacturer Resilience are expanding their partnership with a $750 million investment to increase production of diabetes and obesity injectables

Amgen (NASDAQ: AMGN) is betting that the convenience of its weight loss treatment will make it a winner, and it might be right. Its candidate MariTide is a monthly injection that aims to directly challenge the anti-obesity drugs made by Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), which in their original formulations are…

Amgen(NASDAQ: AMGN) is betting that the convenience of its weight loss treatment will make it a winner, and it might be right. Its candidate MariTide is a monthly injection that aims to directly challenge the anti-obesity drugs made by Eli Lilly(NYSE: LLY) and Novo Nordisk(NYSE: NVO), which in their original formulations are administered by a…

S&P 500LLY 14 min read | July 27, 2026 01:56 AM PDT | By Anmol Khazanchi Google News:

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge

Eli Lilly and Intuitive Surgical Are Healthcare Stocks Worth Buying, Thanks to Strong Fundamentals | NAI 500

Investing.com — Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and verify manufacturing and quality-control data required by regulators

In today’s Pharmaceutical Executive Daily, Eli Lilly’s Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume to Australia and China, and a pharmacy benefits executive weighs in on why short-term cost thinking is complicating GLP-1 coverage decisions

Eli LillyLLYfell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The drug targets three metabolic hormones, GLP-1, GIP and glucagon, against two for Lilly’s current Zepbound and one for Novo…